BRIEF-Novartis says data reinforces ‍Cosentyx effectiveness

Jan 16 (Reuters) – Novartis AG:

* NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS

* ‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​

* ‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)



Learn More about best forex signal provider

What do you think?

0 points
Upvote Downvote

Total votes: 0

Upvotes: 0

Upvotes percentage: 0.000000%

Downvotes: 0

Downvotes percentage: 0.000000%

Nikkei hits highest level since 1991 as dollar weakening stops

Hugo Boss reports sales recovery for stores, U.S. market